Möchten Sie immer auf dem neuesten Stand bleiben?

Neurona Therapeutics presents new positive clinical data from 1st cohort in Ph I/II Trial of NRTX-1001 for drug reistant focal epilepsy at AES meeting

First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress

Neurona Therapeutics CEO to participate in October Investor Conferences

Publication of preclinical studies supporting ongoing open-label first-in-human Phase I/II trial of cell therapy for drug-resistant focal epilepsy

SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...

Promising reduction (>95%) in seizure frequency at the key one-year post treatment endpoint in the first patient to receive NRTX-1001, memory improvements, and seizure-freedom since seven-months...

NRTX-1001 administration is well-tolerated with continued seizure reduction of >90% in the first two patients at nine- and five-months post-treatment, respectively Impaired-awareness seizures...

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...

NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment, respectively Data & Safety Monitoring Board...

NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...